Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$5.63 - $8.27 $103,941 - $152,680
-18,462 Reduced 7.28%
235,205 $1.59 Million
Q3 2023

Nov 14, 2023

SELL
$6.71 - $11.83 $4,307 - $7,594
-642 Reduced 0.25%
253,667 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $1.35 Million - $2.7 Million
121,654 Added 91.71%
254,309 $2.91 Million
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $602,588 - $743,407
32,224 Added 32.09%
132,655 $2.67 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $1.82 Million - $2.74 Million
100,431 New
100,431 $2.28 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.